Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contezolid-acefosamil (Primary) ; Contezolid-acefosamil (Primary) ; Linezolid; Linezolid
  • Indications Cellulitis; Erysipelas; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections; Wound infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MicuRx Pharmaceuticals

    • Most Recent Events

    • 09 Sep 2019 Primary endpoint has been met. (Incidence of treatment-emergent adverse events (safety and tolerability))
    • 09 Sep 2019 Primary endpoint has been met. (Early clinical response in the ITT population)
    • 09 Sep 2019 Top-line results published in the MicuRx Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top